Curis Inc (CRIS) - Total Assets
Based on the latest financial reports, Curis Inc (CRIS) holds total assets worth $29.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CRIS operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Curis Inc - Total Assets Trend (1999–2025)
This chart illustrates how Curis Inc's total assets have evolved over time, based on quarterly financial data. See CRIS total equity for net asset value and shareholders' equity analysis.
Curis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Curis Inc's total assets of $29.69 Million consist of 34.6% current assets and 65.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $8.98 Million | 45.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Curis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRIS market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curis Inc's current assets represent 34.6% of total assets in 2025, a decrease from 74.7% in 1999.
- Cash Position: Cash and equivalents constituted 25.4% of total assets in 2025, up from 9.5% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 45.0% of total assets.
Curis Inc Competitors by Total Assets
Key competitors of Curis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Curis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.23 | 19.90 |
| Quick Ratio | 1.00 | 1.23 | 19.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.00K | $4.69 Million | $148.67 Million |
Curis Inc - Advanced Valuation Insights
This section examines the relationship between Curis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -51.6% |
| Total Assets | $19.97 Million |
| Market Capitalization | $16.63 Million USD |
Valuation Analysis
Near Book Valuation: The market values Curis Inc's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Curis Inc's assets decreased by 51.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Curis Inc (1999–2025)
The table below shows the annual total assets of Curis Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.97 Million | -51.62% |
| 2024-12-31 | $41.27 Million | -46.60% |
| 2023-12-31 | $77.28 Million | -29.00% |
| 2022-12-31 | $108.85 Million | -32.93% |
| 2021-12-31 | $162.30 Million | -20.58% |
| 2020-12-31 | $204.36 Million | +482.10% |
| 2019-12-31 | $35.11 Million | -6.04% |
| 2018-12-31 | $37.37 Million | -49.37% |
| 2017-12-31 | $73.80 Million | +27.78% |
| 2016-12-31 | $57.75 Million | -39.19% |
| 2015-12-31 | $94.97 Million | +51.67% |
| 2014-12-31 | $62.61 Million | -22.31% |
| 2013-12-31 | $80.59 Million | +15.16% |
| 2012-12-31 | $69.98 Million | +45.25% |
| 2011-12-31 | $48.18 Million | -4.87% |
| 2010-12-31 | $50.65 Million | +40.31% |
| 2009-12-31 | $36.10 Million | -9.71% |
| 2008-12-31 | $39.98 Million | -25.71% |
| 2007-12-31 | $53.82 Million | +2.96% |
| 2006-12-31 | $52.27 Million | -14.19% |
| 2005-12-31 | $60.91 Million | -9.94% |
| 2004-12-31 | $67.63 Million | +21.35% |
| 2003-12-31 | $55.74 Million | -10.74% |
| 2002-12-31 | $62.44 Million | -56.86% |
| 2001-12-31 | $144.76 Million | -20.76% |
| 2000-12-31 | $182.68 Million | +532.29% |
| 1999-12-31 | $28.89 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more